COVID-19 Update

Combatting Future Viral Threats with Vaccine Advances

The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.

What’s Next for COVID-19 Vaccines and Variants?

More technologies and treatments are emerging for COVID-19—along with new variants.

Key Elements for Assay Transfer Success

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.

Keeping Europe’s Medicines Stocked

March 02, 2023

Technological advances will help ease pressure on pharma supply chains, allowing for greater visibility and less uncertainty.

Combatting Future Viral Threats with Vaccine Advances

February 03, 2023

The COVID-19 pandemic has led to many changes and shifts in the pharmaceutical industry, specifically with how pharmaceutical companies develop vaccines.

FDA Seeks to Simplify COVID-19 Vaccination Program

January 30, 2023

FDA plans to authorize a common bivalent shot that targets both the original COVID-19 strain and Omicron subvariants.

Providing a Snapshot of the Industry

January 20, 2023

CRB’s latest industry report includes an expanded audience to include many European countries, which has provided some interesting insights.

Opening Up Opportunities in 2023

January 03, 2023

Bio/pharma has evolved and adapted to a variety of challenges in 2022, but what might be on the cards for the industry in 2023?

Crossing the Same River Multiple Times

January 03, 2023

Cautiously setting aside pandemic practices, pharma workers appear ready for flux, change, evolution, and expanding molecular diversity.

FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region

December 20, 2022

FDA has announced that bebtelovimab is not currently authorized for emergency use in any region of the US.

Trial Decline

November 02, 2022

Industry and the government must work closely to ensure the UK remains a competitor in the clinical research field.

EMA Extends Use of COVID-19 Vaccines to Children

October 21, 2022

The agency has recommended approval of Comirnaty and Spikevax for children from six months of age.

EMA Recommends Adapted Spikevax Vaccine

October 21, 2022

The agency has recommended authorization of the Spikevax COVID-19 vaccine that targets the Omicron variants BA.4 and BA.5.